Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine https://kusajili.fr:443/Trial/E79RBL2Nr02EFVxLQjMhsw%24a-phase-iii-double-blind-placebo-controlled-randomised-trial-to-determine-the-efficacy-and-safety-of-a-dose-range-of-50-to-100-
I have read and accept the terms of use of the site and the Privacy Policy
Send your message